A randomized, open-label, phase II study assessing the efficacy and the safety of bevacizumab in neoadjuvant therapy in patients with FIGO stage IIIc/IV ovarian, tubal, or peritoneal adenocarcinoma, initially unresectable

Category Primary study
JournalJournal of Clinical Oncology
Year 2014
This article has no abstract
Epistemonikos ID: f8519e729dbb66b37d5b4a361288e65769ecdaf7
First added on: Feb 06, 2025